Atrial Fibrillation
Rate · Rhythm · Anticoagulation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults, affecting an estimated 33 million people worldwide and 1–2% of the US population — a number expected to double by 2050 as the population ages and obesity becomes more prevalent.[1] The defining problem is not the rhythm itself but what it does downstream: chaotic atrial contraction allows blood to pool and clot in the left atrial appendage, a blind-ended pouch that becomes a factory for thrombus. That thrombus can embolize to the cerebral circulation, and AF accounts for approximately 15–20% of all ischemic strokes — strokes that tend to be larger and more disabling than those from other causes. The cardinal management triad is rate control (slowing the ventricular response), rhythm control (restoring and maintaining sinus rhythm where it improves symptoms or outcomes), and anticoagulation (preventing thromboembolism in patients at sufficient stroke risk).[1] Getting all three decisions right — and knowing when each takes priority — is the central clinical challenge of this disease.
In the late 19th century, a Scottish general practitioner named James Mackenzie sat in his consulting room in Burnley and studied polygraph tracings — simultaneous records of the arterial and jugular venous pulsations — in patients with chaotically irregular pulses. What he saw was the complete absence of the "a wave," the small presystolic bump in the jugular venous tracing caused by organized atrial contraction. He recognized it as auricular paralysis: the atria were not contracting in any coordinated way. Crucially, he observed that the presystolic murmur of mitral stenosis — which depends on atrial contraction to push blood across the narrowed valve — disappeared entirely when this rhythm was present, only to return when the heart converted back to sinus rhythm. This was the first clear clinical demonstration that the atria were electrically quiescent during what we now call atrial fibrillation.[2]
The mechanism remained inferential until Willem Einthoven perfected his string galvanometer — a device sensitive enough to record the minute electrical currents of the beating heart. According to Bishop and Neilson's History of Cardiology (1927), Einthoven modified a string galvanometer so that the motion of the string caused by the minute current from the beating heart could be photographed and recorded mechanically: "With this improvement in our means of diagnosis of heart conditions an enormous field has been opened up. Conditions hitherto unclassified or unknown have now been clarified." Auricular flutter and fibrillation were among the first arrhythmias elucidated and confirmed experimentally by this apparatus.[2] The ECG signature — chaotic fibrillatory baseline replacing discrete P waves, with irregularly irregular QRS complexes — was soon established as the gold standard for diagnosis, a standard that has not changed in a century.
For most of the 20th century, the central clinical question was whether restoring and maintaining sinus rhythm would improve survival over simply controlling the ventricular rate. The hypothesis was intuitively appealing: sinus rhythm should preserve atrial contribution to cardiac output and eliminate the need for anticoagulation. The AFFIRM trial answered this definitively in 2002, randomizing 4,060 patients with AF and stroke risk factors to rhythm control versus rate control over five years. Mortality was statistically identical — and actually numerically favored the rate control group (21.3% vs 23.8%).[3] Simultaneously, the RACE trial confirmed that rate control was non-inferior to rhythm control in persistent AF, with fewer adverse drug effects.[4] The conclusion was jarring but instructive: the antiarrhythmic drugs of that era carried toxicity that neutralized the benefit of sinus rhythm itself.
The field did not stop there. Catheter ablation — physically isolating pulmonary vein triggers from the atrial myocardium — changed the calculus. And in patients with AF and heart failure with reduced ejection fraction, where the interaction between the two conditions is particularly malignant, the CASTLE-AF trial demonstrated in 2018 that ablation-based rhythm control reduced death and heart failure hospitalization by nearly 40%.[5] The 2023 ACC/AHA guideline now designates catheter ablation a Class I therapy for symptomatic paroxysmal AF — a landmark shift from the AFFIRM era.[6]
Normal sinus rhythm depends on the sinoatrial node firing at a regular rate and the resulting electrical wavefront spreading across both atria simultaneously, producing coordinated atrial contraction. In AF, this orderly sequence collapses. The best-understood trigger mechanism involves rapidly firing ectopic foci near the ostia of the pulmonary veins — muscular sleeves extending into the pulmonary veins that have electrophysiological nonuniformities predisposing to focal ectopy and micro-reentry.[1] These rapid triggers interact with the atrial myocardium to produce chaotic, multifocal wavelet activity at 400–600 impulses per minute. The AV node, unable to transmit most of these impulses, acts as a gatekeeper — allowing only a fraction through to the ventricles, producing the characteristic irregularly irregular ventricular rate.
Two direct consequences follow from loss of organized atrial contraction. First, cardiac output falls modestly — typically 10–20% — because the atrial "kick" (the final 20–30% of ventricular filling contributed by atrial systole) is lost. In a healthy young heart, this is well tolerated. In an older or diseased heart with impaired diastolic filling, the loss of the atrial kick can precipitate pulmonary congestion or frank heart failure. Second, blood stagnates in the left atrial appendage, a narrow, irregular pouch with sluggish flow during AF — conditions ideal for thrombus formation. LAA thrombus is the source of the majority of cardioembolic strokes attributable to AF.[1]
Atrial remodeling is the self-perpetuating consequence of AF itself, captured in Allessie's phrase "AF begets AF." Persistent rapid atrial activation shortens the atrial refractory period (electrical remodeling), reduces calcium current, and eventually causes fibrosis and structural remodeling that makes the atrium progressively more hospitable to AF maintenance and less amenable to cardioversion. This is why paroxysmal AF, if untreated, often progresses to persistent and ultimately permanent AF over years. The implication is practical: the substrate for AF is not fixed — it is dynamic and time-dependent. Early rhythm control, before significant atrial remodeling has occurred, is more effective and durable than rhythm control attempted after years of persistent AF.
A second sustaining mechanism — distinct from the pulmonary vein trigger model — involves localized rotational drivers or focal high-frequency sources within the atrial body. These drivers activate too rapidly for surrounding tissue to maintain 1:1 conduction, causing the surrounding tissue to fibrillate. This mechanism explains why pulmonary vein isolation (PVI) alone is curative in the majority of paroxysmal AF patients but is insufficient in many with persistent AF, where substrate within the atrial body has developed independently of pulmonary vein triggers. The autonomic nervous system adds further complexity: vagally-mediated AF (occurring during sleep, after meals, or with bradycardia) and adrenergically-mediated AF (exercise-related, anxiety-related) reflect distinct trigger profiles and may respond differently to pharmacologic and ablation-based approaches.[1]
The ACC/AHA 2023 guideline uses a classification based on temporal pattern and reversibility — with direct implications for cardioversion timing, anticoagulation commitment, and choice of rhythm control strategy.[6]
| Type | Definition | Cardioversion | Anticoagulation Note |
|---|---|---|---|
| Paroxysmal | Self-terminating within 7 days; episodes often end within 48 hours | May convert spontaneously; cardioversion if symptomatic or hemodynamically significant | Stroke risk persists even between episodes; CHA₂DS₂-VASc drives decision |
| Persistent | Sustained >7 days; requires intervention (pharmacologic or electrical) to terminate | Cardioversion after 3 weeks therapeutic OAC, or TEE to exclude LAA thrombus | Continue OAC ≥4 weeks post-cardioversion regardless of CHA₂DS₂-VASc score |
| Long-Standing Persistent | Continuous AF >12 months; rhythm control still pursued | Cardioversion or ablation; atrial remodeling reduces success rates | Indefinite OAC if CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) |
| Permanent | Accepted by patient and provider; no further rhythm control strategy pursued | Not pursued — rate control only | Indefinite OAC if CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) |
Rapid ventricular rate with hemodynamic instability — hypotension, acute pulmonary edema, angina, or impaired consciousness — requires immediate synchronized DC cardioversion regardless of anticoagulation status. This is an emergency. Do not wait for three weeks of anticoagulation. Perform cardioversion at 200 J biphasic; anticoagulate as soon as clinically feasible afterward and continue for a minimum of 4 weeks (atrial stunning persists after cardioversion and the LAA remains thrombogenic even after electrical sinus rhythm is restored).
For pre-excited AF (AF with WPW syndrome): AV nodal blocking agents — beta-blockers, diltiazem, verapamil, digoxin — are absolutely contraindicated. They slow conduction through the AV node while leaving the accessory pathway uninhibited, potentially accelerating ventricular rates to >300 bpm and precipitating ventricular fibrillation. Treat with immediate electrical cardioversion or IV procainamide.
The classic bedside finding is an irregularly irregular pulse with a pulse deficit — the radial pulse rate is lower than the apical rate because some cardiac contractions are too weak to generate a detectable peripheral pulse. The absent a-wave on jugular venous pulsation reflects loss of organized atrial contraction — the same finding that led MacKenzie to his original insight. The 12-lead ECG is definitive for diagnosis.[1]
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Irregularly irregular pulse | ~94% | ~72% | Most sensitive bedside finding; a perfectly regular pulse makes AF highly unlikely |
| Pulse deficit (apical > radial rate) | ~75% | High | Contractions with short preceding RR intervals generate insufficient stroke volume to transmit to radial artery |
| Absent a-wave on JVP | ~60% | ~85% | MacKenzie's original clinical observation; loss of organized atrial contraction abolishes presystolic jugular venous a-wave |
| Variable S1 intensity | ~65% | Moderate | Mitral valve position at onset of systole varies with preceding RR interval; longer RR = wider mitral valve opening = louder S1 |
| Absent presystolic murmur in MS | ~80% (in MS patients) | High | Presystolic component of MS murmur requires atrial contraction — its disappearance in a patient with MS strongly suggests AF |
ECG Features of AF: (1) Absence of discrete P waves — replaced by irregular fibrillatory f-waves at 400–600/min, best seen in V1 and inferior leads; (2) Irregularly irregular RR intervals — the sine qua non of AF; (3) Narrow QRS unless aberrant conduction or pre-excitation is present. A rapid, regular, narrow-complex rhythm in a patient with AF suggests conversion to flutter or junctional rhythm and should be reassessed. A regular, wide-complex tachycardia in AF suggests pre-excitation (WPW) — treat as an emergency.
Bedside ultrasound does not diagnose AF — the ECG does. But cardiac POCUS answers four clinically urgent questions that directly guide management: How enlarged is the left atrium (reflecting chronicity and substrate)? Is LV function impaired (suggesting rate-related cardiomyopathy or pre-existing structural disease)? Is there RV strain (suggesting concurrent pulmonary hypertension or PE)? What is the volume status (guiding rate control strategy and fluid management)?[7]
Pearl 1 — Left Atrial Size on Parasternal Long Axis. The LA diameter is measured in M-mode or 2D at end-systole on the parasternal long axis view (PLAX), from the posterior aortic wall to the posterior LA wall. Normal anteroposterior dimension is <4.0 cm (or LA volume index <34 mL/m²). An enlarged LA (>4.5 cm) predicts lower cardioversion success and higher AF recurrence after ablation — the remodeled atrium is harder to maintain in sinus rhythm. Document LA size at every new AF presentation. Acquire the PLAX view with the probe at the 3rd–4th left intercostal space, marker pointing toward the patient's right shoulder, and marker on the screen positioned on the right of the display.[7]
Pearl 2 — LV Ejection Fraction for Tachycardia-Mediated Cardiomyopathy. Rapid AF with uncontrolled ventricular rate can produce a reversible dilated cardiomyopathy — tachycardia-mediated cardiomyopathy (TMC) — that exactly mimics ischemic or idiopathic dilated cardiomyopathy on echo. Use the parasternal short axis or apical 4-chamber view to estimate EF by eye. A dilated, globally hypokinetic LV in a patient with persistent rapid AF is TMC until proven otherwise. The key distinguishing feature is reversibility — EF normalizes within weeks to months of rate or rhythm control. Do not commit to ICD implantation before a trial of adequate rate control in this setting.[7]
Pearl 3 — RV Assessment for Concurrent Pulmonary Pathology. On the apical 4-chamber view, the RV should be less than two-thirds the size of the LV. An RV:LV ratio >1 with flattening of the interventricular septum (D-sign on parasternal short axis) suggests elevated RV pressure. Acute PE is an important and underrecognized trigger of new-onset AF — POCUS evidence of RV strain in a patient with new AF should prompt CT pulmonary angiography.
Pearl 4 — IVC for Volume Status Guidance. Use the subcostal IVC view to assess right atrial pressure before initiating rate-controlling agents. A plethoric, non-collapsing IVC (>2.1 cm with <50% collapse on sniff) suggests elevated RA pressure and guides cautious diuresis before or alongside rate control. A collapsing, small IVC (<1.5 cm with >50% collapse) suggests relative hypovolemia and should prompt reassessment before aggressive diuresis.[7]
Every patient with new or newly recognized AF warrants a structured evaluation to identify reversible precipitants and establish baseline parameters for management decisions.[1] Hyperthyroidism causes AF in >16% of affected patients; thyrotoxicosis-induced AF may resolve entirely with normalization of thyroid function and should not prompt indefinite rhythm control or long-term anticoagulation commitments until thyroid status is controlled. Additional reversible causes include acute alcohol intoxication ("holiday heart"), pericarditis, myocarditis, post-operative inflammation, PE, electrolyte disturbance, and medication toxicity.
| Test | Clinical Rationale |
|---|---|
| TSH | Hyperthyroidism is the most common endocrine cause; thyrotoxicosis-induced AF often reverts with treatment — do not commit to antiarrhythmic therapy until thyroid function is confirmed normal |
| CBC | Anemia can trigger or worsen AF; leukocytosis suggests acute infection or myocarditis; thrombocytopenia affects anticoagulant selection and safety |
| BMP / Magnesium | Hypokalemia and hypomagnesemia promote atrial ectopy and AF recurrence; replete magnesium to >2.0 mEq/L; creatinine dictates DOAC dosing and identifies patients requiring warfarin or DOAC dose reduction |
| Troponin / BNP | Troponin to exclude ACS as precipitant; BNP reflects hemodynamic burden — elevated BNP in rapid AF suggests rate-related cardiomyopathy or underlying HF and guides urgency of rate control |
| Transthoracic echocardiogram | Mandatory in all new AF: assess LA size, LV/RV function, valvular disease, wall motion abnormalities; guides rhythm vs rate decision; identifies structural substrate; informs anticoagulation risk-benefit discussion |
| Ambulatory cardiac monitoring | Holter (24–48 hr), extended event monitor (30 days), or wearable patch (up to 14 days) — quantifies AF burden, distinguishes paroxysmal from persistent AF when resting ECG is normal; smartwatch ECG apps increasingly capture AF before clinical presentation |
| Sleep study (consider) | OSA highly prevalent in AF population; CPAP reduces AF burden and progression; untreated OSA significantly worsens outcomes of rhythm control strategies including ablation |
Managing AF requires three simultaneous and often interdependent decisions: ventricular rate control, rhythm control, and anticoagulation. These are not sequential — all three must be addressed at initial presentation and re-evaluated with every clinical change. A fourth pillar, lifestyle modification, is now formally recognized in the 2023 ACC/AHA guideline as essential to durable AF management.[6]
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| Rate Control — Beta-Blockers | First-line for most patients. Target resting HR <110 bpm (lenient) or <80 bpm if symptoms persist. Metoprolol succinate, carvedilol, atenolol. IV metoprolol for acute rate control in the ED. | Preferred in HFrEF (carvedilol, metoprolol succinate). Avoid in decompensated HF or acute bronchospasm. RACE confirmed rate control strategy non-inferior to rhythm control in persistent AF.[4] |
| Rate Control — Non-DHP Calcium Channel Blockers | Diltiazem or verapamil for rate control when beta-blockers contraindicated or insufficient. IV diltiazem effective for acute rate control. Oral diltiazem extended-release for chronic management. | Absolutely contraindicated in HFrEF — negative inotropy worsens LV function. Contraindicated in pre-excited AF (WPW). Effective for rate control in structurally normal hearts and HFpEF.[4] |
| Rate Control — Digoxin | Third-line adjunct; controls resting HR but not exercise HR. 0.125–0.25 mg daily with renal dose adjustment. Check levels; narrow therapeutic index (target 0.5–0.9 ng/mL). | Reserve for patients intolerant of beta-blockers and CCBs, or as add-on therapy. Provides AV nodal blockade via vagotonic mechanism — ineffective during high sympathetic tone (exercise, illness).[1] |
| Rhythm Control — Electrical Cardioversion (ECV) | 200 J biphasic synchronized shock under procedural sedation. Requires ≥3 weeks therapeutic OAC or TEE to exclude LAA thrombus if AF duration >48 hr or unknown. Continue OAC ≥4 weeks after ECV. | Most effective acute method for rhythm restoration. AFFIRM: no mortality benefit of rhythm control over rate control strategy when using antiarrhythmic drugs.[3] Atrial stunning mandates 4-week post-ECV anticoagulation. |
| Rhythm Control — Antiarrhythmic Drugs | Flecainide or propafenone (structurally normal heart only; CI in CAD). Sotalol (renal dose adjustment; QTc monitoring). Dronedarone (avoid in permanent AF or HFrEF). Amiodarone (most effective; reserved for HFrEF or failed alternatives due to toxicity). | AFFIRM: antiarrhythmic drug toxicity (pulmonary, thyroid, hepatic, neurologic for amiodarone) offsets sinus rhythm benefit. Flecainide CI in structural heart disease — risk of proarrhythmia. Amiodarone requires annual surveillance for end-organ toxicity.[3] |
| Rhythm Control — Catheter Ablation (PVI) | Radiofrequency or cryoballoon ablation to electrically isolate pulmonary vein ostia. Now Class I first-line rhythm control for symptomatic paroxysmal AF per 2023 guideline. Refer early — substrate progresses with time. | CABANA: no ITT reduction in MACE in all-comers with AF[8]; CASTLE-AF: 38% reduction in death/HF hospitalization in AF + HFrEF (EF ≤35%).[5] 2023 ACC/AHA: Class I for symptomatic paroxysmal AF; Class I for AF + HFrEF.[6] |
| Anticoagulation — Warfarin | Target INR 2.0–3.0. Mandatory in patients with mechanical valves or moderate-to-severe mitral stenosis (DOACs not approved). Monthly INR monitoring. Multiple drug-drug and drug-food interactions. | 64% relative risk reduction in stroke vs. placebo in landmark AF trials. Now generally superseded by DOACs in non-valvular AF due to superior safety profiles, fixed dosing, and no need for monitoring.[1] |
| Anticoagulation — Dabigatran | 150 mg BID (standard); 110 mg BID if age >80, low body weight, or high bleeding risk. Direct thrombin inhibitor. No routine monitoring required. Avoid if CrCl <15 mL/min. Reversal agent: idarucizumab. | RE-LY (n=18,113): 150 mg superior to warfarin for stroke/systemic embolism (RR 0.66, p<0.001); 110 mg non-inferior with significantly less major bleeding than warfarin.[9] |
| Anticoagulation — Rivaroxaban | 20 mg once daily with evening meal. Factor Xa inhibitor. Reduce to 15 mg once daily if CrCl 15–50 mL/min. Reversal agent: andexanet alfa. | ROCKET-AF (n=14,264): non-inferior to warfarin for stroke/systemic embolism; similar major bleeding; fewer intracranial hemorrhages and fatal bleeding events with rivaroxaban.[10] |
| Anticoagulation — Apixaban | 5 mg BID; reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL. Factor Xa inhibitor. Often preferred in CKD. Reversal agent: andexanet alfa. | ARISTOTLE (n=18,201): superior to warfarin for stroke/SE (HR 0.79, p=0.01), significantly less major bleeding (HR 0.69, p<0.001), and lower all-cause mortality (HR 0.89, p=0.047).[11] |
| CHA₂DS₂-VASc Scoring & Anticoagulation Threshold | Score ≥2 (men) or ≥3 (women): anticoagulate. Score 1 (men) or 2 (women): discuss risk-benefit; shared decision-making. Score 0 (men) or 1 (women — female sex alone): anticoagulation not recommended. Recalculate at each visit. | C=CHF(1), H=HTN(1), A=Age≥75(2), D=DM(1), S=Stroke/TIA(2), V=Vascular disease(1), A=Age 65–74(1), Sc=Sex category female(1). Maximum 9 points. DOACs preferred over warfarin for all non-valvular AF. 2023 ACC/AHA Class I, Level A.[6] |
| Lifestyle Modification | Weight loss ≥10% in obese patients; treat OSA with CPAP; limit alcohol to ≤1 drink/day; treat hypertension aggressively; moderate aerobic exercise (high-intensity endurance training paradoxically increases AF risk); smoking cessation. | 2023 ACC/AHA guideline designates lifestyle modification the fourth pillar of AF management alongside rate, rhythm, and anticoagulation — Class I recommendation.[6] Weight loss ≥10% body weight associated with 50% reduction in AF symptom burden in observational data. |
| Recommendation — ACC/AHA/ACCP/HRS 2023 Guideline[6] | Class | Level of Evidence |
|---|---|---|
| Anticoagulation with DOACs preferred over warfarin in eligible non-valvular AF patients | I | A |
| Anticoagulation recommended for AF patients with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) | I | A |
| Catheter ablation (PVI) as first-line rhythm control for symptomatic paroxysmal AF | I | A |
| Catheter ablation recommended to reduce mortality and HF hospitalization in AF + HFrEF (EF ≤35%) | I | B-R |
| Lifestyle modification (weight loss, exercise, alcohol reduction, OSA treatment) as fourth pillar of AF management | I | B-R |
| Rate control with beta-blocker or non-dihydropyridine CCB for ventricular rate management | I | B-R |
| Early rhythm control strategy preferred in recently diagnosed AF (<1 year) with cardiovascular risk factors | IIa | B-R |
| LAA occlusion (WATCHMAN) for patients with high stroke risk and contraindication to long-term OAC | IIa | B-R |
| Anticoagulation not recommended in AF without additional stroke risk factors (CHA₂DS₂-VASc 0 in men, 1 in women — female sex alone) | III: Harm | B-NR |
The AFFIRM trial's conclusion — that rhythm control confers no mortality benefit over rate control — reshaped AF management for two decades. But the lesson requires careful reading. AFFIRM enrolled patients with a mean age of 70 in predominantly persistent or longstanding AF. More importantly, rhythm control meant chronic antiarrhythmic drug therapy in 2002: amiodarone, sotalol, dofetilide, and their contemporaries. The trial demonstrated that these drugs were toxic enough to neutralize the benefit of sinus rhythm itself. It was not a verdict on sinus rhythm — it was a verdict on the tools then available to achieve it.[3]
CASTLE-AF told a different story precisely because it used a different tool. This trial enrolled 363 patients with symptomatic AF, LVEF ≤35%, and an implanted ICD or CRT-D providing objective arrhythmia monitoring. Catheter ablation reduced the composite of all-cause death or hospitalization for worsening heart failure by 38% (28.5% vs 44.6%; p=0.006) over a median of 38 months. All-cause mortality was nearly halved (13.4% vs 25.0%, p=0.01).[5] The mechanism was not merely rate control — the ablation group spent dramatically more time in sinus rhythm, and freedom from AF was the strongest predictor of improved EF and outcomes on post-hoc device analysis.
Why do these two trials diverge so sharply? Three mechanisms stand out. First, catheter ablation avoids the systemic drug toxicity that undermined AFFIRM's rhythm control arm. Second, patients with HFrEF tolerate loss of atrial contribution to cardiac output poorly — the 10–20% cardiac output reduction from AF matters far more in a heart with EF 25% than in a heart with EF 60%. Third, AF and HFrEF interact in a vicious cycle: rapid AF worsens LV function (tachycardia-mediated cardiomyopathy), and a failing, dilated LV stretches the atria and perpetuates AF substrate. Catheter ablation can interrupt this cycle in ways that drugs cannot.
The 2023 ACC/AHA guideline reflects this evidence directly: catheter ablation is now a Class I recommendation for AF patients with HFrEF (EF ≤35%). Clinically, this means the question is not "should we pursue rhythm control?" but "when should we refer for ablation?" The answer is early — before atrial remodeling and further LV dysfunction reduce the probability of durable success. The EAST-AFNET 4 trial (2020) extended this logic beyond HFrEF, showing that early rhythm control within 1 year of AF diagnosis reduced the composite of cardiovascular death, stroke, and heart failure hospitalization by 21% compared to rate control alone, even in patients without established HFrEF. The old AFFIRM logic holds only when rhythm control means chronic antiarrhythmic drug therapy in a patient who has lived with AF for years. It does not hold for ablation at the right time in the right patient.[6]
4,060 patients randomized to rate or rhythm control. No mortality benefit from rhythm control; hospitalizations higher with antiarrhythmic drugs. Foundational trial that defined a generation of AF management.
Apixaban superior to warfarin for stroke/SE prevention, with less major bleeding and lower all-cause mortality in 18,201 AF patients. Established apixaban as preferred DOAC for most patients.
Catheter ablation vs. medical therapy in AF + HFrEF (EF ≤35%). 38% reduction in death or HF hospitalization. Near-halving of all-cause mortality. Changed the guideline recommendation for ablation in HF.
2,204 patients randomized to ablation vs antiarrhythmic drugs. No ITT reduction in primary MACE endpoint; per-protocol and on-treatment analyses favored ablation. Informs shared decision-making for ablation candidacy in non-HF patients.
[1] Sauer WH, Zei PC. Chapter 253: Approach to Supraventricular Arrhythmias. In: Loscalzo J, et al., eds. Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill, 2022. [Also cross-referenced with: Curtis AB, Baykaner T, Narayan SM. Chapter 36: Atrial Fibrillation and Atrial Flutter. In: Fuster V, et al., eds. Fuster and Hurst's The Heart, 15th ed. McGraw Hill, 2022.]
[2] Bishop LF, Neilson J Jr. History of Cardiology. Medical Life Press, New York, 1927. [MacKenzie's polygraph observations establishing auricular paralysis (AF); Einthoven's string galvanometer and ECG clarification of arrhythmias including auricular flutter and fibrillation.]
[3] Wyse DG, Waldo AL, DiMarco JP, et al. (AFFIRM Investigators). A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33. PMID: 12466506. [PubMed]
[4] Van Gelder IC, Hagens VE, Bosker HA, et al. (RACE Study Group). A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40. PMID: 12466507. [PubMed]
[5] Marrouche NF, Brachmann J, Andresen D, et al. (CASTLE-AF Investigators). Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27. PMID: 29385358. [PubMed]
[6] Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. PMID: 38033089. [PubMed]
[7] Istrail L. The POCUS Textbook: Learn Point-of-Care Ultrasound of the Blood Vessels, Heart, & Lungs. ZeroGray Publishing, 2025. ISBN: 979-8-218-68730-4. [Buy on Amazon] Chapters 13 (Cardiac Views), 14 (Estimating Left Ventricular Ejection Fraction), 15 (Volume Overload and Venous Congestion).
[8] Packer DL, Mark DB, Robb RA, et al. (CABANA Investigators). Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74. PMID: 30874766. [PubMed]
[9] Connolly SJ, Ezekowitz MD, Yusuf S, et al. (RE-LY Steering Committee and Investigators). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. PMID: 19717844. [PubMed]
[10] Patel MR, Mahaffey KW, Garg J, et al. (ROCKET AF Investigators). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. PMID: 21830957. [PubMed]
[11] Granger CB, Alexander JH, McMurray JJV, et al. (ARISTOTLE Committees and Investigators). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. PMID: 21870978. [PubMed]